AIM: We analysed the impact of tobacco smoking over several healthy lifestyle habits along with the impact on 10-years cardiovascular event (CVE) risk in the CLAMORS schizophrenia cohort. METHODS: This analysis was performed within the scope of the CLAMORS study which included consecutive outpatients meeting DSM-IV criteria for schizophrenia spectrum disorder. Beside smoking history, data on usual healthy lifestyle habits included current exercise, saturated fat sparing diet, low-caloric diet, and daily dietary fibre, salt, caffeine and alcohol consumption were recorded. The 10-year CVE risk was calculated with Framingham function. RESULTS: 1704 patients (61.1% male), 18 to 74 years were examined. Prevalence of smoking was 54.54% (95% CI: 52.16%-56.90%) significantly higher than in age and sex matched general population subjects, 31.51% (31.49%-31.52%); OR=2.61 (2.37-2.87, p<0.0001). After controlling by confounders smokers showed a 10-year CVE risk excess versus non-smokers of 2.63 (2.16-3.09), p<0.001. Smoking cessation would reduce the likely of high/very high 10-year CVE risk (above 10%) by near 90% [OR=0.10 (0.06-0.18), p<0.0001]. Also, smokers were more likely to consume alcohol daily [4.13 (3.07-5.54), p<0.0001] and caffeine [3.39 (2.72-4.23), p<0.0001] than non-smoker patients with schizophrenia, and less likely to avoid daily consumption of salt [0.58 (0.43-0.78), p<0.0001], saturated fat [0.71 (0.56-0.91), p=0.006], high fibre diet [0.67 (0.53-0.84), p=0.001], or to follow a low-caloric diet [0.63 (0.48-0.81), p<0.0001]. Smokers also were less likely to do exercise habitually [0.62 (0.48-0.82, p=0.001]. CONCLUSION: Compared with the general population, patients with schizophrenia showed significant higher prevalence of smoking. Smokers who stop smoking would benefit by a near 90% reduction in the likely of 10-year cardiovascular event risk above 10%. Copyright (c) 2010 Elsevier B.V. All rights reserved.
AIM: We analysed the impact of tobacco smoking over several healthy lifestyle habits along with the impact on 10-years cardiovascular event (CVE) risk in the CLAMORS schizophrenia cohort. METHODS: This analysis was performed within the scope of the CLAMORS study which included consecutive outpatients meeting DSM-IV criteria for schizophrenia spectrum disorder. Beside smoking history, data on usual healthy lifestyle habits included current exercise, saturated fat sparing diet, low-caloric diet, and daily dietary fibre, salt, caffeine and alcohol consumption were recorded. The 10-year CVE risk was calculated with Framingham function. RESULTS: 1704 patients (61.1% male), 18 to 74 years were examined. Prevalence of smoking was 54.54% (95% CI: 52.16%-56.90%) significantly higher than in age and sex matched general population subjects, 31.51% (31.49%-31.52%); OR=2.61 (2.37-2.87, p<0.0001). After controlling by confounders smokers showed a 10-year CVE risk excess versus non-smokers of 2.63 (2.16-3.09), p<0.001. Smoking cessation would reduce the likely of high/very high 10-year CVE risk (above 10%) by near 90% [OR=0.10 (0.06-0.18), p<0.0001]. Also, smokers were more likely to consume alcohol daily [4.13 (3.07-5.54), p<0.0001] and caffeine [3.39 (2.72-4.23), p<0.0001] than non-smoker patients with schizophrenia, and less likely to avoid daily consumption of salt [0.58 (0.43-0.78), p<0.0001], saturated fat [0.71 (0.56-0.91), p=0.006], high fibre diet [0.67 (0.53-0.84), p=0.001], or to follow a low-caloric diet [0.63 (0.48-0.81), p<0.0001]. Smokers also were less likely to do exercise habitually [0.62 (0.48-0.82, p=0.001]. CONCLUSION: Compared with the general population, patients with schizophrenia showed significant higher prevalence of smoking. Smokers who stop smoking would benefit by a near 90% reduction in the likely of 10-year cardiovascular event risk above 10%. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Authors: Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll Journal: World Psychiatry Date: 2011-06 Impact factor: 49.548
Authors: Warren K Bickel; David P Jarmolowicz; E Terry Mueller; Mikhail N Koffarnus; Kirstin M Gatchalian Journal: Pharmacol Ther Date: 2012-02-22 Impact factor: 12.310
Authors: Eun Young Kim; Se Hyun Kim; Nam Young Lee; Jin Sang Yoon; Chul Eung Kim; Yong Sik Kim; Yong Min Ahn Journal: Psychopharmacology (Berl) Date: 2014-05-13 Impact factor: 4.530
Authors: Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert Journal: Schizophr Bull Date: 2011-12-29 Impact factor: 9.306
Authors: Gladys N Pachas; Corinne Cather; Sarah A Pratt; Bettina Hoeppner; Johanna Nino; Sara V Carlini; Eric D Achtyes; Harry Lando; Kim T Mueser; Nancy A Rigotti; Donald C Goff; A Eden Evins Journal: J Dual Diagn Date: 2012-05-11
Authors: Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten Journal: Psychopharmacology (Berl) Date: 2013-08-21 Impact factor: 4.530